JP4409936B2 - 血小板アデノシン二リン酸受容体アンタゴニスト - Google Patents

血小板アデノシン二リン酸受容体アンタゴニスト Download PDF

Info

Publication number
JP4409936B2
JP4409936B2 JP2003501845A JP2003501845A JP4409936B2 JP 4409936 B2 JP4409936 B2 JP 4409936B2 JP 2003501845 A JP2003501845 A JP 2003501845A JP 2003501845 A JP2003501845 A JP 2003501845A JP 4409936 B2 JP4409936 B2 JP 4409936B2
Authority
JP
Japan
Prior art keywords
aminocarbonyl
ethoxycarbonyl
piperazin
carbonyl
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003501845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532886A (ja
JP2004532886A5 (https=
Inventor
エー． ブライアント，ジュディ
オー． バックマン，ブラッド
イスラム，イマドゥル
モハン，ラジュ
エム． モーリッシー，マイケル
ピン ウェイ，グオ
シュウ，ウェイ
ユアン，シェンドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of JP2004532886A publication Critical patent/JP2004532886A/ja
Publication of JP2004532886A5 publication Critical patent/JP2004532886A5/ja
Application granted granted Critical
Publication of JP4409936B2 publication Critical patent/JP4409936B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
JP2003501845A 2001-06-06 2002-06-06 血小板アデノシン二リン酸受容体アンタゴニスト Expired - Fee Related JP4409936B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29649801P 2001-06-06 2001-06-06
US10/163,742 US6861424B2 (en) 2001-06-06 2002-06-05 Platelet adenosine diphosphate receptor antagonists
PCT/US2002/017821 WO2002098856A2 (en) 2001-06-06 2002-06-06 Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists

Publications (3)

Publication Number Publication Date
JP2004532886A JP2004532886A (ja) 2004-10-28
JP2004532886A5 JP2004532886A5 (https=) 2009-08-20
JP4409936B2 true JP4409936B2 (ja) 2010-02-03

Family

ID=26859907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003501845A Expired - Fee Related JP4409936B2 (ja) 2001-06-06 2002-06-06 血小板アデノシン二リン酸受容体アンタゴニスト

Country Status (5)

Country Link
US (4) US6861424B2 (https=)
EP (1) EP1412349A2 (https=)
JP (1) JP4409936B2 (https=)
AU (1) AU2002316191A1 (https=)
WO (1) WO2002098856A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511519A (ja) * 2002-12-11 2006-04-06 シエーリング アクチエンゲゼルシャフト 血小板アデノシン二リン酸受容体アンタゴニストとしての２−アミノカルボニルキノリン化合物

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2005009971A1 (ja) * 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
EP1812429A4 (en) * 2004-09-29 2010-07-21 Portola Pharm Inc SUBSTITUTED 2H-1,3-BENZOXAZIN-4 (3H) -ONE
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
US7826982B2 (en) * 2005-07-29 2010-11-02 Children's Hospital Medical Center Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
AU2006305538B2 (en) 2005-10-21 2012-06-28 Idorsia Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
US20100210635A1 (en) * 2006-03-29 2010-08-19 Takeda Pharmaceutical Company Limited Renin inhibitors
US20070254861A1 (en) * 2006-04-28 2007-11-01 Astellas Pharma Inc. Methods for the prevention and/or treatment of peripheral arterial disease
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) * 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
EP1967513A1 (en) * 2007-03-08 2008-09-10 Rheinische Friedrich-Wilhelms-Universität Bonn Novel P2Y12 receptor antagonists
MX2009011089A (es) * 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
AU2008266515B2 (en) 2007-06-18 2014-05-01 Sanofi Pyrrole derivatives as P2Y12 antagonists
EP2225253B1 (en) * 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
EP2238128B1 (en) * 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) * 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20100160323A1 (en) * 2008-12-23 2010-06-24 Alexander Bischoff NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
US8729095B2 (en) 2009-08-28 2014-05-20 Daiichi Sankyo Company, Limited 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
AU2010341537A1 (en) 2009-12-22 2012-08-09 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
US8889688B2 (en) 2010-01-05 2014-11-18 Actelion Pharmaceuticals Ltd. Piperazines as antimalarial agents
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
GB201218084D0 (en) * 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
CN105189485B (zh) 2013-03-15 2017-10-24 埃科特莱茵药品有限公司 作为抗疟剂的新型丙烯酰胺衍生物
EP3515924B1 (en) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Crystalline forms
MA49887A (fr) 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
US20220402916A1 (en) * 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2022140464A1 (en) * 2020-12-22 2022-06-30 Immunomolecular Therapeutics, Inc. Compounds and methods for treating autoimmune disorders by targeting hla-dq2
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1334705A (en) 1970-06-19 1973-10-24 Ici Ltd Pharmaceutical compositions containing kynurenic acid derivatives
US4258192A (en) 1977-12-16 1981-03-24 Mitsubishi Chemical Industries Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
AU8868991A (en) 1990-11-15 1992-06-11 Pentapharm Ag Meta-substituted phenyl alanine derivatives
JPH07509731A (ja) 1993-02-10 1995-10-26 ペンタファルム　アクチェンゲゼルシャフト トロンビン阻害剤としての置換されたフェニルアラニン誘導体のピペラジド
KR0173034B1 (ko) 1995-04-28 1999-03-30 성재갑 선택적 트롬빈 억제제
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
JP2003502314A (ja) * 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511519A (ja) * 2002-12-11 2006-04-06 シエーリング アクチエンゲゼルシャフト 血小板アデノシン二リン酸受容体アンタゴニストとしての２−アミノカルボニルキノリン化合物

Also Published As

Publication number Publication date
WO2002098856A2 (en) 2002-12-12
US20050065163A1 (en) 2005-03-24
US7176207B2 (en) 2007-02-13
AU2002316191A1 (en) 2002-12-16
JP2004532886A (ja) 2004-10-28
US6995156B2 (en) 2006-02-07
WO2002098856A3 (en) 2004-03-04
US20050038037A1 (en) 2005-02-17
US6861424B2 (en) 2005-03-01
EP1412349A2 (en) 2004-04-28
US7026323B2 (en) 2006-04-11
US20030060474A1 (en) 2003-03-27
US20060135532A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
JP4409936B2 (ja) 血小板アデノシン二リン酸受容体アンタゴニスト
JP4662777B2 (ja) 血小板アデノシン二リン酸受容体アンタゴニストとしての２−アミノカルボニルキノリン化合物
DE69730490T2 (de) Aminoheterocyclische verbindungen als antithrombotisches oder antikoagulierendes mittel
US6277862B1 (en) Quinoline derivatives
CZ158098A3 (cs) Chinolin-4-karboxamidové deriváty, způsob jejich přípravy, farmaceutický prostředek a použití jako antagonistů receptorů neurokininu 3(NK-3) a 2(NK-2)
WO2003000660A1 (fr) Derive de quinoleine et derive de quinoleine permettant d'inhiber l'auto-phosphorylation du recepteur des proliferateurs des hepatocytes, ainsi que des compositions medicinales contenant ce derive
ES2201509T3 (es) Derivados de quinolina-4-carboxamida como antagonista de los receptores nk-2 y nk-3.
JP2002521375A (ja) 化合物
JPH11269140A (ja) 分化誘導剤
US5399703A (en) Tetrazole derivatives and drugs
JP2006518362A (ja) Ｎｋ−２／ｎｋ−３受容体リガンドとしての置換キノリン−４−カルボン酸ヒドラジド
JP2719740B2 (ja) 強心剤
JPH07501532A (ja) 抗喘息性，および気管支抗炎症作用を有する［３Ｈ，７Ｈ］チアゾール［３，４‐ａ］ピリジン

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090409

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091013

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091112

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121120

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees